Chris Okonis

insights and analytics lead at Dicerna Pharmaceuticals, Inc. - Lexington, Massachusetts, US

Chris Okonis's Colleagues at Dicerna Pharmaceuticals, Inc.
Gloria Jimenez

quality assurance specialist contractor

Contact Gloria Jimenez

Sunish Raj

Director, Clinical Data Management

Contact Sunish Raj

Dennis L.

Senior Manager, Information Technology

Contact Dennis L.

Chris R.

Senior Manager - R&D Finance and Accounting

Contact Chris R.

Robert Fronk

Senior Talent Acquisition Specialist

Contact Robert Fronk

Marina Zhang

Senior Quality Manager

Contact Marina Zhang

Halla D

Program Management & Development

Contact Halla D

View All Chris Okonis's Colleagues
Chris Okonis's Contact Details
HQ
(617) 621-8097
Location
Company
Dicerna Pharmaceuticals, Inc.
Chris Okonis's Company Details
Dicerna Pharmaceuticals, Inc. logo, Dicerna Pharmaceuticals, Inc. contact details

Dicerna Pharmaceuticals, Inc.

Lexington, Massachusetts, US • 500 - 999 Employees
Major Drugs

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, we discover and develop innovative RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, our GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, we have continued to innovate and are exploring new applications of our RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology to tissues and cell types outside the liver with the potential to treat diseases across multiple therapeutic areas. Our team brings together talented experts across the fields of biology, chemistry, clinical science, medicine and more. With decades of scientific and technical experience focused on RNAi technology, we have the knowledge and experience needed to discover and develop therapies for patients with serious unmet medical needs. Between our own pipeline of core discovery and clinical candidates and those developed through collaborative relationships with some of the world’s leading pharmaceutical companies, we have generated more than 20 active discovery, preclinical or clinical proprietary and collaborative programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.

Targeted Cancer Therapies Rare Disease Neurodegenerative Diseases
Details about Dicerna Pharmaceuticals, Inc.
Frequently Asked Questions about Chris Okonis
Chris Okonis currently works for Dicerna Pharmaceuticals, Inc..
Chris Okonis's role at Dicerna Pharmaceuticals, Inc. is insights and analytics lead.
Chris Okonis's email address is ***@dicerna.com. To view Chris Okonis's full email address, please signup to ConnectPlex.
Chris Okonis works in the Major Drugs industry.
Chris Okonis's colleagues at Dicerna Pharmaceuticals, Inc. are Gloria Jimenez, Sunish Raj, Dennis L., Chris R., Robert Fronk, Marina Zhang, Halla D and others.
Chris Okonis's phone number is ["+15085232400","+19784150173"]
See more information about Chris Okonis